JNJ Valuation Metrics
JNJ Stock Price Metrics
JNJ Dividend Metrics
JNJ Growth Rate Metrics
JNJ Discounted Cash Flow Metrics
| Fair Value Price | $322.46 |
| Margin of Safety | 35.21% |
JNJ Revenue Metrics
JNJ PE Ratio Metrics
| PE Ratio | 27.79 |
| PE Ratio Avg TTM | 20.76 |
| PE Ratio Avg 3Y | 19.80 |
| Current VS TTM Avg | +33.90% |
| Current VS 3Y Avg | +40.39% |
| Current VS 5Y Avg | +26.98% |
JNJ PS Ratio Metrics
| PS Ratio | 6.10 |
| PS Ratio Avg TTM | 5.35 |
| PS Ratio Avg 3Y | 4.76 |
| Current VS TTM Avg | +14.05% |
| Current VS 3Y Avg | +28.11% |
| Current VS 5Y Avg | +26.70% |
JNJ PB Ratio Metrics
| PB Ratio | 7.24 |
| PB Ratio Avg TTM | 6.21 |
| PB Ratio Avg 3Y | 5.69 |
| Current VS TTM Avg | +16.57% |
| Current VS 3Y Avg | +27.22% |
| Current VS 5Y Avg | +23.07% |
JNJ Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 33.02 |
| PFCF Ratio Avg TTM | 27.09 |
| PFCF Ratio Avg 3Y | 23.87 |
| Current VS TTM Avg | +21.90% |
| Current VS 3Y Avg | +38.32% |
| Current VS 5Y Avg | +40.79% |
JNJ Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.59 |
| Debt/Equity Ratio Avg TTM | 0.55 |
| Debt/Equity Ratio Avg 3Y | 0.51 |
| Current VS TTM Avg | +7.27% |
| Current VS 3Y Avg | +15.12% |
| Current VS 5Y Avg | +15.31% |
JNJ PEG Ratio Metrics
| PEG Ratio | 0.21 |
| PEG Ratio Avg TTM | 0.21 |
| PEG Ratio Avg 3Y | 0.21 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
JNJ FCF Yield
| FCF Yield | 3.03% |
| FCF Yield Avg TTM | 3.75% |
| FCF Yield Avg 3Y | 4.32% |
| Current VS TTM Avg | -19.25% |
| Current VS 3Y Avg | -29.87% |
| Current VS 5Y Avg | -30.55% |
JNJ Earnings Yield
| Earnings Yield | 3.60% |
| Earnings Yield Avg TTM | 4.90% |
| Earnings Yield Avg 3Y | 5.96% |
| Current VS TTM Avg | -26.50% |
| Current VS 3Y Avg | -39.62% |
| Current VS 5Y Avg | -30.66% |
JNJ EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 22.54 |
| Ev/Ebit Ratio Avg TTM | 21.55 |
| Ev/Ebit Ratio Avg 3Y | 19.02 |
| Current VS TTM Avg | +4.58% |
| Current VS 3Y Avg | +18.51% |
| Current VS 5Y Avg | +15.63% |
JNJ EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 18.67 |
| Ev/Ebitda Ratio Avg TTM | 14.03 |
| Ev/Ebitda Ratio Avg 3Y | 15.52 |
| Current VS TTM Avg | +33.12% |
| Current VS 3Y Avg | +20.27% |
| Current VS 5Y Avg | +15.74% |
JNJ EV/Assets Ratio Metrics
| Ev/Assets Ratio | 2.90 |
| Ev/Assets Ratio Avg TTM | 2.65 |
| Ev/Assets Ratio Avg 3Y | 2.39 |
| Current VS TTM Avg | +9.47% |
| Current VS 3Y Avg | +21.35% |
| Current VS 5Y Avg | +16.80% |
JNJ EV/Sales Ratio Metrics
| Ev/Sales Ratio | 6.06 |
| Ev/Sales Ratio Avg TTM | 5.60 |
| Ev/Sales Ratio Avg 3Y | 4.96 |
| Current VS TTM Avg | +8.28% |
| Current VS 3Y Avg | +22.18% |
| Current VS 5Y Avg | +20.54% |
JNJ Current Ratio Metrics
| Current Ratio | 1.03 |
| Current Ratio Avg TTM | 1.07 |
| Current Ratio Avg 3Y | 1.07 |
| Current VS TTM Avg | -3.74% |
| Current VS 3Y Avg | -3.96% |
| Current VS 5Y Avg | -9.78% |
JNJ Quick Ratio Metrics
| Quick Ratio | 0.77 |
| Quick Ratio Avg TTM | 0.81 |
| Quick Ratio Avg 3Y | 0.84 |
| Current VS TTM Avg | -5.52% |
| Current VS 3Y Avg | -8.06% |
| Current VS 5Y Avg | -15.38% |
JNJ ROIC Metrics
| ROIC | 13.71% |
| ROIC Avg 3Y | 14.10% |
| ROIC Avg 5Y | 13.87% |
| Current VS 3Y Avg | -2.73% |
| Current VS 5Y Avg | -1.18% |
| Current VS 10Y Avg | +6.77% |
JNJ Return on Assets Metrics
| ROA | 13.46 |
| ROA Avg TTM | 10.63 |
| ROA Avg 3Y | 12.96 |
| Current VS TTM Avg | +26.56% |
| Current VS 3Y Avg | +3.90% |
| Current VS 5Y Avg | +12.64% |
JNJ Return on Equity Metrics
| ROE | 32.87 |
| ROE Avg TTM | 26.27 |
| ROE Avg 3Y | 31.76 |
| Current VS TTM Avg | +25.10% |
| Current VS 3Y Avg | +3.51% |
| Current VS 5Y Avg | +10.51% |
JNJ Net Profit Margin Metrics
| Net Profit Margin | 28.46% |
| Net Profit Margin Avg TTM | 22.15% |
| Net Profit Margin Avg 3Y | 27.00% |
| Current VS TTM Avg | +28.49% |
| Current VS 3Y Avg | +5.40% |
| Current VS 5Y Avg | +12.08% |
Last Updated: Thursday, June 11, 2026
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato